AN2 Therapeutics, Inc. (ANTX)

NASDAQ: ANTX · USD

$4.53

+0.67 (+17.4%)· Recorded snapshot

Market cap	170.9M
Net income (ttm)	-36.3M
EPS (ttm)	-$1.04
Shares out	37.7M
Volume	511,431
Beta	-0.98

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -36.3M
EPS (ttm): -$1.04
Market cap: 170.9M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Trzymaj

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-50.1

P25 -113.8P50 -46.5P75 -0.9

ROIC-33.5

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All ANTX indicators

Market & fundamental data

Available fields

171

Groups with data

Currency

USD

Showing 171 of 171 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001880438
Company name	AN2 Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	037326105
Earnings date	2026-11-11
Earnings time	amc
Employees	21
Employees change	-1
Employees growth	-4.55%
Enterprise value	$92.6M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2017
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2022-03-25
Is primary listing	Yes
Is SPAC	No
ISIN number	US0373261058
Last 10-K release date	2026-03-17
Last earnings date	2026-08-11
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$170.9M
Market cap category	Micro-Cap
Next earnings date	2026-11-11
Options	Yes
Price	$4.53
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	ANTX
U.S. state	California
Website	https://www.an2therapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-22.96%
FCF / EV yield	-45.61%
FCF yield	-21.06%
P/B ratio	1.85x
Price / tangible book value	1.92x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.7M
ROA	-30.8%
ROA (5Y)	-33.36%
ROCE	-51.01%
ROE	-50.12%
ROE (5Y)	-55.88%
ROIC	-33.51%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	2
EPS growth years	4
Net income growth years	2
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	$-38.8M
EPS	$-1.04
FCF per share	$-0.81
Financing cash flow	$38.9M
Free cash flow	$-30.7M
Free cash flow minus SBC	$-35.3M
Investing cash flow	$17.9M
Net cash flow	$26.1M
Net income	$-36.3M
Operating cash flow minus SBC	$-35.3M
Operating income	$-38.8M
Stock-based compensation	$4.6M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$2.09
Debt / equity	0
Long-term assets	$1.7M
Long-term liabilities	$170,000
Net cash (debt)	$78.4M
Net cash / market cap	53.81%
Net cash growth	24.59%
Net debt / equity	-1.03
Piotroski F-Score	2
Shareholders' equity	$75.9M
Tangible book value	$75.9M
Tangible book value per share	$2.09
Total assets	$81.7M
Total cash	$78.4M
Total debt	$0
Total liabilities	$5.8M
WACC	-1.12%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$80M
Current liabilities	$5.6M
Current ratio	14.32
Net working capital	$-4M
Quick ratio	14.09
Working capital	$74.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-16.31%
Dividend yield	0%
Shareholder yield	-16.31%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$4.69
1D price change	17.36%
1M price change	-8.81%
1M total return	-8.81%
1W price change	25%
1W total return	25%
1Y price change	229.63%
1Y return CAGR	229.9%
1Y total return	229.63%
20-day SMA	$4.20
200-day SMA	$4.04
3M price change	-9.74%
3M total return	-9.74%
3Y price change	-69.37%
3Y return CAGR	-32.59%
3Y total return	-69.37%
50-day SMA	$4.95
50-day SMA vs 200-day SMA	50over200
52-week high	$7.19
52-week high date	2026-08-12
52-week low	$1.00
52-week low date	2026-02-19
6M price change	-7.29%
6M total return	-7.29%
All-time high	$23.58
All-time high date	2022-05-16
All-time low	$0.87
All-time low date	2024-08-09
Average true range (ATR)	$0.34
Average volume	318.3K
Beta (1Y)	-2.04
Beta (2Y)	-0.19
Beta (5Y)	-0.98
Change from 52-week high	-37%
Change from 52-week low	353%
Change from all-time high	-81.13%
Change from all-time low	411.49%
Change from open	13.25%
Day's gap	3.63%
Dollar volume	$2.3M
High price	$4.60
Low price	$4.00
Monthly RSI	51.83
Open price	$4.00
Position in 52-week range	88.33%
Premarket change	4.15%
Premarket close	$3.86
Premarket price	$4.02
Previous close	$3.86
Price vs 150-day SMA	-5.16%
Price vs 20-day SMA	5.93%
Price vs 200-day SMA	10.23%
Price vs 50-day SMA	-10.01%
Relative volume	1.61
Return from IPO open	-77.09%
Return from IPO price	-74.27%
RSI	53.41
Sharpe ratio	1.39
Sharpe ratio (3Y)	0.24
Sortino ratio	3.93
Sortino ratio (3Y)	0.43
Volume	511.4K
Weekly RSI	50.17
YTD price change	290.35%
YTD total return	290.35%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	22.3M
Float percentage	59.06%
Shares change (QoQ)	31.42%
Shares change (YoY)	16.31%
Shares held by insiders	4.91%
Shares held by institutions	47.22%
Shares outstanding	37.7M
Short % of float	11.18%
Short % of shares	6.6%
Short ratio	10.7 days

Deeper analysis on ANTX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ANTX report

Is a complete ANTX research report available?

No complete published report is available for AN2 Therapeutics, Inc. (ANTX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

AN2 Therapeutics, Inc. (ANTX)

Price

Financial snapshot

Fair-value bridge

Latest news · ANTX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ANTX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ANTX

Frequently asked questions